Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

. 2023 Mar 10 ; 41 (8) : 1600-1609. [epub] 20221122

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid36413710

PURPOSE: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS: CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS: At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION: D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).

Komentář v

PubMed

Komentář v

PubMed

Zobrazit více v PubMed

de Weers M, Tai YT, van der Veer MS, et al. : Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840-1848, 2011 PubMed

Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. : Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 124:3474, 2014

Overdijk MB, Verploegen S, Bögels M, et al. : Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7:311-321, 2015 PubMed PMC

Overdijk MB, Jansen JH, Nederend M, et al. : The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking. J Immunol 197:807-813, 2016 PubMed

Krejcik J, Casneuf T, Nijhof IS, et al. : Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128:384-394, 2016 PubMed PMC

Adams HC, III, Stevenaert F, Krejcik J, et al. : High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A 95:279-289, 2019 PubMed PMC

Casneuf T, Adams HC, III, van de Donk NWCJ, et al. : Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia 35:573-584, 2021 PubMed PMC

Kinder M, Bahlis NJ, Malavasi F, et al. : Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. Haematologica 106:2004-2008, 2021 PubMed PMC

Moreau P, Attal M, Hulin C, et al. : Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study. Lancet 394:29-38, 2019 PubMed

Mateos MV, Cavo M, Blade J, et al. : Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. Lancet 395:132-141, 2020 PubMed

Facon T, Kumar S, Plesner T, et al. : Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104-2115, 2019 PubMed PMC

Mateos MV, Sonneveld P, Hungria V, et al. : Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: Three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 20:509-518, 2020 PubMed

Bahlis NJ, Dimopoulos MA, White DJ, et al. : Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34:1875-1884, 2020 PubMed PMC

Dimopoulos MA, Terpos E, Boccadoro M, et al. : Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial. Lancet Oncol 22:801-812, 2021 PubMed

DARZALEX® (daratumumab) [package insert]. Horsham, PA, Janssen Biotech, Inc, 2022

European Medicines Agency : DARZALEX 20 mg/mL concentrate for solution for infusion [summary of product characteristics]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004077/WC500207296.pdf

Palumbo A, Chanan-Khan A, Weisel K, et al. : Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375:754-766, 2016 PubMed

Spencer A, Lentzsch S, Weisel K, et al. : Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR. Haematologica 103:2079-2087, 2018 PubMed PMC

Weisel KC, Sonneveld P, Mateos MV, et al. : Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): Four-year update of CASTOR. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando, FL, December 7-10, 2019

Durie BGM, Harousseau JL, Miguel JS, et al. : International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 PubMed

Rajkumar SV, Harousseau JL, Durie B, et al. : Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 117:4691-4695, 2011 PubMed PMC

Facon T, Kumar SK, Plesner T, et al. : Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22:1582-1596, 2021 PubMed

Siegel DS, Dimopoulos MA, Ludwig H, et al. : Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36:728-734, 2018 PubMed

Dimopoulos MA, Lonial S, White D, et al. : Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 10:91, 2020 PubMed PMC

Orlowski RZ, Moreau P, Niesvizky R, et al. : Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk 19:522-530.e1, 2019 PubMed

Dimopoulos MA, Oriol A, Nahi H, et al. : Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319-1331, 2016 PubMed

Dimopoulos MA, Oriol A, Nahi H, et al. : Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open‐label, phase III trial. J Clin Oncol 41:1590-1599, 2023 PubMed PMC

Yong K, Delforge M, Driessen C, et al. : Multiple myeloma: Patient outcomes in real-world practice. Br J Haematol 175:252-264, 2016 PubMed PMC

Fonseca R, Usmani SZ, Mehra M, et al. : Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 20:1087, 2020 PubMed PMC

Suzuki K, Nishiwaki K, Yano S: Treatment strategies considering micro-environment and clonal evolution in multiple myeloma. Cancers (Basel) 13:215, 2021 PubMed PMC

Nooka AK, Joseph NS, Kaufman JL, et al. : Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer 125:2991-3000, 2019 PubMed

Hussain MJ, Robinson MM, Hamadeh I, et al. : Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma. Br J Haematol 186:140-144, 2019 PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02136134

Najít záznam

Citační ukazatele

    Možnosti archivace